SCM Life Science, a Korean company founded in 2014 with focus on the isolation of high-purity homogeneous stem cells for therapeutic purposes, will go public on the secondary Kosdaq in March.

It will offer 1.8 million shares in initial public offering with an aim to raise 32.4 billion won ($27.4 million) as pricing is proposed from 15,500 won to 18,000 won, according to its IPO registration filed with the Financial Services Commission.

The IPO led by Korea Investment & Securities will hold bookbuilding session on March 9-10 and offer to the public on March 16-17.

By Pulse

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]